J&J/Merck
This article was originally published in The Tan Sheet
Executive Summary
Form OTC joint venture in the U.K. called Centra Healthcare. Among the first products to be marketed by Centra is an OTC version of Merck's H[2] antagonist Pepcid (famotidine), which was recently cleared for over-the-counter status in the U.K. Centra will be headed by Collin Mackenzie and is expected to begin marketing products in the first quarter of 1994.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning